[ad_1]
There are an increasing number of pharmaceutical companies taking the IPO route to increase their research and development activities – this trend continues in 2023. There are many biotech companies looking to go public this year, and Cadrenal Therapeutics, Inc. is one of them.
Cadrenal is developing a new therapy to prevent heart-related blood clots, especially in patients with advanced kidney disease and atrial fibrillation. Currently, the company’s main product is in the development stage. Before reaching the market, it must go through various stages such as clinical trials and FDA approval. So, it will be a long time before the company turns a profit and creates meaningful shareholder value.
To raise $7Mln
As part of efforts to speed up the drug development process, the company is poised to raise capital from the public market. According to a revised SEC filing, Cadrenal plans to offer 1.4 million shares in an initial public offering scheduled to take place this month. Earlier, it had announced plans to offer around 2 million shares. The offer price is about $5 per share, which will generate total proceeds of about $7 million.
the result
Funds raised through the offering will be used primarily for research & development as well as meeting expenses related to the preparation of clinical trials.. A portion of the proceeds will be used for working capital and general corporate purposes, including the acquisition or licensing of other products, businesses, or technologies.
After approval by the Securities and Exchange Commission, the shares will be listed on the Nasdaq Capital Market under the symbol cvd. Boustead Securities and Sutter Securities will act as bookrunners for the offering.
IPO sign: MGO Global is ready to go public. Here’s what you need to know
The therapies currently available for atrial fibrillation and end-stage renal disease have side effects, which Cadrenal’s area looks to capitalize on. The company will conduct a phase-III trial of its lead candidate tecarfarin – which is considered more effective and safer — in the fourth quarter of 2023.
Financial Performance
Like most early-stage biopharma companies, Cadrenal has yet to turn a profit because it does not yet have a marketable product. In the eight months ended September 2022, since inception, the company had a net loss of approximately $1.7 million or $0.22 per share, primarily reflecting significant general & administrative and research & development expenses.
[ad_2]
Source link